Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALB | P02768 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501110 | 0.85 | ALDH1A1 (0.41) | LMNAALBALDH1A1MAPK1ABL1 | |
| SCHEMBL4501109 | 0.85 | ALDH1A1 (0.41) | LMNAALBALDH1A1MAPK1ABL1 | |
| SCHEMBL23258398 | 0.85 | LMNA (0.43) | LMNAALBALDH1A1MAPK1ABL1 | |
| SCHEMBL5638638 | 0.84 | LMNA (0.42) | LMNAALBALDH1A1MAPK1ABL1 | |
| SCHEMBL9545096 | 0.84 | LMNA (0.42) | LMNAALBALDH1A1MAPK1ABL1 | |
| SCHEMBL9392057 | 0.82 | ALDH1A1 (0.39) | LMNAALBALDH1A1MAPK1ABL1 | |
| SCHEMBL14154578 | 0.82 | LMNA (0.39) | LMNAALBALDH1A1MAPK1ABL1 | |
| SCHEMBL3953383 | 0.82 | ALDH1A1 (0.39) | LMNAALBALDH1A1MAPK1ABL1 | |
| SCHEMBL7595956 | 0.82 | — | — | |
| SCHEMBL2873282 | 0.78 | LMNA (0.52) | LMNACYP1A2TSHRTK1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112672764-A | Conjugates | 格莱科斯生物医药公司 | 2021-04-16 | — | — | CN | claimed |
| US-9198893-B2 | Combination antitumor therapy | GALERA LABS, LLC (US) | 2015-12-01 | — | — | US | claimed |
| US-20110136756-A1 | COMBINATION ANTITUMOR THERAPY | BIOSSIL INC. (CA) | 2011-06-09 | — | — | US | claimed |
| EP-2296645-A2 | COMBINATION ANTITUMOR THERAPY | Kereos, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009143454-A2 | COMBINATION ANTITUMOR THERAPY | KEREOS, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-1495325-B1 | USE OF NUCLOEOSIDE DERIVATIVES COMPRISING A CITRATE GROUP FOR PRODUCING ANTIBODIES HAVING AFFINITY FOR TRIPHOSPHORYLATED NUCLEOSIDES AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2009-05-13 | — | — | EP | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-1194168-A2 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078941-A2 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2000-12-28 | — | — | WO | claimed |
| EP-4746875-A2 | CARCINOGENESIS REDUCTION WITH PENTAAZA MACROCYCLIC RING COMPLEX | Galera Labs, LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3921420-B1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-5449664-A | Nucleosides | SYNTEX (U.S.A.) INC. (US) | 1995-09-12 | — | — | US | disclosed |
| WO-1992017485-A1 | PREPARATION OF 3'-SUBSTITUTED-2',3'-DIDEOXYNUCLEOSIDES AND 2'-DEOXYNUCLEOSIDES FROM ACYCLIC, ACHIRAL PRECURSORS | EMORY UNIVERSITY (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0482081-A1 | ANTIVIRAL COMPOSITION. | HARMENBERG JOHAN (SE) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991001137-A1 | ANTIVIRAL COMPOSITION | HARMENBERG JOHAN (SE) | 1991-02-07 | — | — | WO | disclosed |
| EP-0332626-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS IN HUMANS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | CYP4X1, SLC6A7, ZFX | LMNA 3499/4885ALB 4828/4885ALDH1A1 503/4885 |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | PHAX, RNMT, PRKCZ | LMNA 630/4885ALB 4356/4885ALDH1A1 4778/4885 |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | LMNA 3759/4885ALB 497/4885ALDH1A1 2841/4885 |
| US-20110136756-A1 | COMBINATION ANTITUMOR THERAPY | SOD3, SOD1, MCL1 | LMNA 3699/4885ALB 3527/4885ALDH1A1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.